Viking Therapeutics (VKTX) Q2 2026 earnings summary

Executive summary

• Advanced lead compound VK2735 in both injectable and oral formulations for obesity, with phase III VANQUISH trials fully enrolled and oral phase III initiation expected in Q4 2026.

• Initiated a phase I trial for VK3019, a dual amylin and calcitonin receptor agonist, expanding the clinical obesity portfolio.

• Expanded leadership with key executive hires and board appointments, including a new chief medical officer and Dorothy Kelly-Gemmell.

• No revenue generated to date; operations funded by equity offerings and investments.

• Report covers the quarter ended June 30, 2026, for a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders.

Financial highlights

• Research and development expenses rose to $115.8M for Q2 2026 (vs. $60.2M in Q2 2025) and $266M for the first half of 2026 (vs. $101.5M in 2025), mainly due to increased clinical activity and staffing.

• General and administrative expenses increased to $16.9M for Q2 2026 (vs. $14.4M in Q2 2025) and $30.9M for the first half (vs. $28.5M in 2025).

• Net loss was $128.1M ($1.10/share) for Q2 2026 (vs. $65.6M, $0.58/share in Q2 2025) and $286.5M ($2.47/share) for the first half (vs. $111.2M, $0.99/share in 2025).

• Cash, cash equivalents, and short-term investments totaled $502M as of June 30, 2026, down from $706M at year-end 2025.

• Interest income declined 49% to $4.6M for Q2 2026 and 45% to $10.4M for the six-month period.

Outlook and guidance

• Phase III oral VK2735 trials are expected to begin in Q4 2026, aiming to be the first oral dual GLP-1/GIP agonist on the market.

• Maintenance dosing study results for VK2735 are expected later in Q3 2026, with further oral maintenance cohorts to complete in 2027.

• Cash runway is projected into 2028, with anticipated reduced cash usage as major phase III trials conclude.

• Management expects current cash resources to fund operations through at least September 30, 2027.

• Anticipates continued operating losses as R&D activities expand, with additional capital raises likely required for future development and commercialization.